Price/Sales of Exelixis, Inc.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
|PLPM Planet Payment, Inc.||NASDAQ > Miscellaneous > Business Services||0.48|
|TRST TrustCo Bank Corp NY||NASDAQ > Finance > Major Banks||0.48|
|SCHL Scholastic Corporation||NASDAQ > Consumer Services > Books||0.48|
|HDNG Hardinge Inc.||NASDAQ > Capital Goods > Industrial Machinery/Components||0.49|
|CLF Cliffs Natural Resources Inc.||NYSE > Basic Industries > Precious Metals||0.49|
|KL Kirkland Lake Gold Ltd.||NYSE > Basic Industries > Precious Metals||0.49|
|EXEL Exelixis, Inc.||NASDAQ > Health Care > Biotechnology: Commercial Physical & Biological Resarch||0.49|
|HCC Warrior Met Coal, Inc.||NYSE > Energy > Coal Mining||102.00|
|WTM White Mountains Insurance Group, Ltd.||NYSE > Finance > Property-Casualty Insurers||128.23|
|NVR NVR, Inc.||NYSE > Capital Goods > Homebuilding||135.95|
|SEB Seaboard Corporation||NYSEMKT > Finance > Investment Bankers/Brokers/Service||279.36|
|DCIX Diana Containerships Inc.||NASDAQ > Transportation > Marine Transportation||648.16|
|BRK-A Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||11,356.35|